The movie about the titular plant showed The Xylom founder Alex Ip the importance of a news media landscape accurately ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

And this highlights how different bacteria work together to thrive in varying soil pH levels.” That finding was novel and important, Gowda said. Bacteria and other microorganisms are known to be ...

Luxury brands are struggling due to economic pressures and high inflation. Aspirational consumers have turned to midlevel brands like Zara and Pandora. Both retailers are thriving, capturing ...

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.

Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity Scientific insights reflect Exact Sciences’ commitment to closing the ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out that marks the first Spanish-language promotional push for the brand.

Investors with a lot of money to spend have taken a bullish stance on Exact Sciences EXAS. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

MADISON, Wis., August 28, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will ...

Exact Sciences has a multipronged approach to cancer ... Despite its acquisitions of Base Genomics and Thrive for a combined total of $2.6 billion, which were announced in 2020, the company ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal ...